1.17

0.85% -0.01

Pre-market: 1.17

Geovax Labs Inc (GOVX)

Overview News Price History Financials Discussions Forecast Stock Split

Geovax Labs Inc stock is traded at $1.17, with a volume of 674.22K. It is down -0.85% in the last 24 hours and down -4.88% over the past month. Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Previous Close:

$1.18

Open:

$1.19

24h Volume:

674.22K

Relative Volume:

0.14

Market Cap:

$6.10M

Revenue:

$852.30K

Net Income/Loss:

$-21.37M

P/E Ratio:

-0.0539

EPS:

-21.6981

Net Cash Flow:

$-19.06M

1W Performance:

-8.59%

1M Performance:

-4.88%

6M Performance:

-83.66%

1Y Performance:

-96.45%

1-Day Range:

$1.12

$1.24

1-Week Range:

$1.12

$1.47

52-Week Range:

$0.9631

$34.25

Geovax Labs Inc Stock (GOVX) Company Profile

Name

Geovax Labs Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

678-384-7220

Address

1955 LAKE PARK DRIVE, SMYRNA

Employee

Twitter

Next Earnings Date

2026-07-27

Latest SEC Filings

GOVX's Discussions on Twitter

Compare GOVX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOVX Geovax Labs Inc	1.17	6.15M	852.30K	-21.37M	-19.06M	-21.70
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Downgrade	D. Boral Capital	Buy → Hold
Apr-15-25	Reiterated	Alliance Global Partners	Buy
Apr-15-25	Reiterated	D. Boral Capital	Buy
Nov-11-24	Initiated	Alliance Global Partners	Buy
Jul-16-24	Initiated	ROTH MKM	Buy
Nov-19-20	Initiated	Maxim Group	Buy

View All

Geovax Labs Inc Stock (GOVX) Latest News

Jun 14, 2026

GOVX Q1 2026 Earnings: EPS Surprise of 41.89% as Loss Narrows from EstimatesConsensus Forecast Report - newsline.com

Jun 14, 2026

GeoVax Labs (GOVX) could find a support soon, here's why you should buy the stock now - MSN

Jun 14, 2026

Jun 12, 2026

GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Jun 12, 2026

Jun 10, 2026

GeoVax Labs Company Profile & Introduction - Moomoo

Jun 10, 2026

Jun 09, 2026

[SCHEDULE 13G] GeoVax Labs, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Jun 09, 2026

Why Is GOVX Stock Falling Today? - Stocktwits

Jun 09, 2026

Jun 08, 2026

Q3 2025 GeoVax Labs Inc Earnings Call Transcript - GuruFocus

Jun 08, 2026

GeoVax Highlights Research Showing Gedeptin Could Enhance Checkpoint Inhibitor Responses in Resistant Tumors - MEXC

Jun 08, 2026

GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses - Yahoo Finance

Jun 08, 2026

Jun 05, 2026

GOVX Q1 2026 Earnings: EPS Surprises to the Upside, Yet Stock Retreats 11.8%EPS Surprise History - newsline.com

Jun 05, 2026

GOVX Technical Analysis | Trend, Signals & Chart Patterns | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill

Jun 04, 2026

Jun 03, 2026

GeoVax CEO Sees Renewed Strategic Focus on Vaccine Platforms Amid Industry Acquisitions - citybuzz -

Jun 03, 2026

GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation - Yahoo Finance

Jun 03, 2026

Jun 01, 2026

GeoVax CEO Highlights Biothreat Readiness as FIFA World Cup 2026 Approaches - MEXC

Jun 01, 2026

GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness - Yahoo Finance

Jun 01, 2026

May 31, 2026

Why is GeoVax Labs stock falling Tuesday? - MSN

May 31, 2026

May 29, 2026

GOVX Q1 2026 Earnings: Narrower-than-Expected Loss as Biotech Advances DevelopmentEarnings Growth Forecast - newsline.com

May 29, 2026

May 28, 2026

GOVX: GEO-MVA advances to phase III with expedited EMA review, targeting unmet global vaccine demand - TradingView

May 28, 2026

Is Co-Diagnostics National Security’s Next Diagnostic Pick? - Investing.com

May 28, 2026

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail

May 28, 2026

May 27, 2026

GeoVax CEO to Discuss Platform-Based Vaccine Technologies in Tribe Public Webinar - citybuzz -

May 27, 2026

Registration Now Open for Tribe Public CEO Presentation and Q&A Webinar Event - NewMediaWire

May 27, 2026